Dennis Yurichev’s blog
-
1
Unpacking a database of unknown type
-
2
Amateur cryptography: decrypting TVT CCTV camera config files
-
3
Making C compiler generate obfuscated code
-
4
Tweaking LLVM Obfuscator + quick look into some of LLVM internals
-
5
Fuzzy string matching + simplest possible spellchecking + hunting for typos and misspellings in Wikipedia
-
6
Typeless programming languages (BCPL, B), C evolution and decompiling
-
7
Content-addressable storage
-
8
Cracking simple LCG PRNG
-
9
Worst sorting algorithm I ever saw: proving it using KLEE
-
10
Generating Malbolge code using simulated annealing
Download 2D Unlock APKs for Android – APKMirror
-
1
HUAWEI Browser 17.0.4.302 by HUAWEI
-
2
HUAWEI Browser 17.0.6.301 by HUAWEI
-
3
HUAWEI AppGallery 16.4.1.301 by HUAWEI
-
4
HUAWEI AppGallery 16.0.1.301 by HUAWEI
-
5
HUAWEI AppGallery 16.1.1.300 by HUAWEI
-
6
HUAWEI AppGallery 16.1.1.301 by HUAWEI
-
7
HUAWEI AppGallery 16.0.1.302 by HUAWEI
-
8
HUAWEI AppGallery 16.2.1.300 by HUAWEI
-
9
HUAWEI HMS Services Framework 11.2.0.300 by HUAWEI
-
10
HUAWEI AppGallery 16.3.1.300 by HUAWEI
eClinicalMedicine
-
1
[Articles] Electroacupuncture for knee osteoarthritis: a multicentre randomised controlled trial assessing symptomatic and structural efficacy
-
2
[Articles] Adverse childhood experiences and risk of non-mental medical diseases in adulthood: an umbrella review
-
3
[Articles] A digitally embedded intervention to enhance psychological decentering and reduce depression severity in at-risk adolescents: a randomised controlled trial of the ‘One Step Back’ programme
-
4
[Articles] Next-step treatment for schizophrenia non-responsive to antipsychotics: a systematic review and network meta-analysis
-
5
[Review] Balancing the benefits and risks of GLP-1 receptor agonists: a clinical guide for shared decision-making
-
6
[Articles] Efficacy and safety of camrelizumab plus apatinib in advanced urachal cancer (RUN-SC-0102): a single-arm, multicentre, phase 2 trial in China
The Lancet
-
1
[Comment] Is ATLAS lifting the burden of stroke in people with large-vessel occlusion and low ASPECTS scores?
-
2
[Articles] Endovascular thrombectomy for patients with large-core ischaemic stroke presenting up to 24 h after onset (ATLAS): a systematic review and individual patient data meta-analysis with central imaging adjudication
-
3
[Department of Error] Department of Error
-
4
[Articles] Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials
-
5
[Comment] Astegolimab and the new era of biologics in COPD care
-
6
[Perspectives] Paul B Spiegel: pioneer in humanitarian health
-
7
[Comment] A much-needed reboot for international solidarity
-
8
[The Lancet Commissions] Johns Hopkins Center for Humanitarian Health–Lancet Commission on health, conflict, and forced displacement: health in a world of crises and impunity
-
9
[Editorial] Transforming the humanitarian system
-
10
[Comment] Transforming the humanitarian system: our role to confront embedded inequities
The Lancet Child & Adolescent Health
-
1
[Viewpoint] Defining and measuring what matters: quality of life for children with disabilities
-
2
[Review] Safety of in vivo gene therapy in children: mechanisms and management of liver injury
-
3
[Comment] Support without identification: a regressive shift in neurodevelopmental care?
-
4
[Comment] Autistic SPACE: clinician advocacy for improving school environments for autistic young people
-
5
[Reflections] Listening to the room
-
6
[Reflections] The war in Ukraine: mental health toll on children and adolescents
-
7
[Articles] Bedside model-informed precision dosing of vancomycin in severely ill neonates and children in Belgium (the BENEFICIAL trial): a multicentre, randomised controlled trial
-
8
[Comment] Model-informed precision dosing: from a niche for pharmacologists to daily business of paediatricians?
-
9
[Articles] Early discontinuation of empirical antibiotics versus extended treatment in children with cancer and high-risk febrile neutropenia in Denmark: an open-label, randomised controlled trial
-
10
[Comment] Paediatric autoimmunity: from single entity to shared vulnerability
The Lancet Diabetes & Endocrinology
-
1
[Corrections] Correction to Lancet Diabetes Endocrinol 2025; 13: 935–48
-
2
[Correspondence] Implications of microplastics as emerging endocrine disruptors
-
3
[Comment] What REDEFINE 5 signals for obesity trials in Asia and beyond
-
4
[Articles] Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, ph
-
5
[Comment] A conceptual framework for modernising and right-sizing global diabetes care
-
6
[Comment] Freedom through technology: transforming management of type 2 diabetes
-
7
[Articles] Continuous glucose monitoring versus self-monitoring of blood glucose in individuals with type 2 diabetes: a randomised, multicentre, open-label, superiority trial
-
8
[Comment] Diabetes in sub-Saharan Africa: aligning biology, culture, and health systems for improved outcomes
-
9
[Articles] Safety, tolerability, pharmacokinetics, and efficacy of burosumab in infants with X-linked hypophosphataemia: an open-label, multicentre, non-randomised study
-
10
[Series] Burden and determinants of diabetes in sub-Saharan Africa
The Lancet Digital Health
-
1
[Articles] AI-based BRAIx risk score for the intermediate-term prediction of breast cancer: a population cohort study
-
2
[Viewpoint] Beyond artificial intelligence psychosis: a functional typology of large language model-associated psychotic phenomena
-
3
[Comment] Artificial intelligence for post-treatment prediction in age-related macular degeneration
-
4
[Articles] Development and validation of a deep learning model to predict visual and anatomical prognosis of anti-VEGF therapy for neovascular age-related macular degeneration (KongMing Study): a prospective, nationwide, multicentre study
-
5
[Articles] Effects of the COVID-19 pandemic on antibiotic use and resistance in French hospitals, 2019–22: a retrospective ecological analysis of national surveillance data
-
6
[Articles] Deep learning model for pathological invasiveness prediction using smartphone-based surgical resection images in clinical stage IA lung adenocarcinoma (SuRImage): a prospective, multicentric, diagnostic study
-
7
[Comment] Can large language models help young researchers develop new clinical research ideas?
-
8
[Editorial] Transforming digital pathology with AI
-
9
[Comment] Digitised histopathology slides now ready for artificial intelligence: predicting the molecular signatures of gliomas
-
10
[Articles] Molecular alterations prediction in gliomas via an interpretable deep learning model: a multicentre and retrospective study
The Lancet Gastroenterology & Hepatology
-
1
[Review] Pharmacotherapy for metabolic dysfunction-associated steatohepatitis: heart–liver co-management
-
2
[Comment] The challenge of defining metabolic dysfunction and alcohol-associated liver disease
-
3
[Comment] Rethinking coeliac disease care: why psychological understanding matters
-
4
[Articles] Binge drinking, metabolic dysfunction, and the spectrum of steatotic liver disease in the USA: a cross-sectional and longitudinal analysis
-
5
[Comment] Long-term progression of steatotic liver disease: multiple drivers of the same disease?
-
6
[Articles] The burden of chronic hepatitis B and C in 2022 and progress towards elimination: a global report
-
7
[Comment] Shared principles within HBV guidelines: aligning clinical approach with differentiated care for global elimination
-
8
[Articles] Robot-assisted versus conventional minimally invasive oesophagectomy for oesophageal squamous cell carcinoma (RAMIE): a multicentre, open-label, randomised, phase 3, non-inferiority trial
-
9
[Articles] Global burden of metabolic dysfunction-associated steatotic liver disease, 1990–2023, and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2023
-
10
[Viewpoint] Rifaximin in cirrhosis: when therapeutic drift meets antimicrobial stewardship